TREATMENT PATTERNS AND OUTCOMES OF ACTHAR GEL IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PHYSICIAN-REPORTED CHART REVIEW
Bibliographic record
Abstract
PV271 / #799 Poster Topic: AS24 - SLE-Treatment Background/Purpose Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune disorders and medical conditions known to cause inflammation, including systemic lupus erythematosus (SLE). This study aims to describe the characteristics of patients with SLE treated with Acthar Gel, utilization patterns of the medication, and physicians’ assessments of its effects on patients’ health status. Methods This study was prospectively designed with a predefined protocol and statistical analysis plan. The study employed a chart review methodology, where 41 U.S. rheumatologists reviewed 56 patient charts for individuals treated with Acthar Gel for SLE within the past 24 months. Patients with known contraindications to Acthar Gel were excluded from the study. In November 2024, physicians searched patient records starting from April 1, 2022. Data included demographics, comorbidities, symptoms, prior treatments and health outcomes following Acthar Gel treatment. Results The study included 56 SLE patients with an average age of 42 years and mean BMI of 27.5 kg/m 2 . Most were female (84%) and African American (50%). Common comorbidities included chronic joint disease (34%), hyperlipidemia (34%), hypertension (34%) and arthritis/osteoarthritis (30%). Prior to Acthar Gel treatment, 63% of patients reported fair-to-poor health status, with a mean rating of 3.6 out of 5 (where 1 = excellent and 5 = poor). Frequent symptoms included joint pain (84%), rashes (68%) and fatigue (68%). Most were previously treated with antimalarial drugs (64%), corticosteroids (64%), immunosuppressive drugs (57%) and biologic disease-modifying antirheumatic drugs (DMARDs) (55%). The average time since diagnosis was 4.8 years and the average duration of Acthar Gel treatment was 8 months. Most patients (91%) were dosed at 40-80 units twice per week. Physicians reported that 89% of patients experienced improved health status after Acthar Gel treatment. Improvements among these patients included overall symptoms (82%), pain (54%), fatigue (44%), reduced corticosteroid use (44%), physical function (38%) and strength (28%). Conclusions This study demonstrates that Acthar Gel is an effective treatment option for SLE. Patients experienced improvements in multiple areas such as symptoms, pain relief, fatigue, reduced corticosteroid use, physical function and strength. These findings underscore the utility of Acthar Gel in enhancing outcomes for patients with SLE.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".